Clinical trial

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

NCT04145570

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-10-23

PhasePHASE4

Study timeline

Study start (actual)2008-10-23Date precision: day

Registry last updated2019-10-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

Interventions

Erlotinib HCl 150 mgDRUG

Tarceva®DRUG

Sponsors & collaborators

Quadras Scientific Solutionslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04145570 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.